ViiV Healthcare Initiates CUSTOMIZE Study of Dual-Drug Injectable Regimen for the Treatment of HIV

 ViiV Healthcare Initiates CUSTOMIZE Study of Dual-Drug Injectable Regimen for the Treatment of HIV

ViiV Healthcare Initiates CUSTOMIZE Study of Dual- Drug Injectable Regimen for the Treatment of HIV

Shots:

  • The CUSTOMIZE study will evaluate the two-drug regimen consisting ViiV’s Cabotegravir and Janssen’s Edurant (rilpivirine) in patients with HIV with suppressed viral load and no resistance to cabotegravir or rilpivirine
  • In Apr’2019, the US FDA has accepted NDA filing of long-acting dual-drug injectable regimen and has granted PR to NDA with its expected PDUFA date as Dec 29, 2019
  • Edurant is an antiretroviral therapy indicated to treat HIV-1 in patients aged ≥ 12 yrs. Cabotegravir is an investigational therapy, being evaluated as an oral therapy & LA injectable for the treatment & prevention of HIV infection

Click here to read full press release/ article | Ref: GSK | Image: Twitter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post